We aspire to be the leading healthcare company focused on innovative treatments for women’s health and prostate cancer designed to improve the lives of millions. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer.
Our lead investigational drug candidate is relugolix, a small molecule, GnRH receptor antagonist. We have three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 & 2), two in women with endometriosis-associated pain (SPIRIT 1 & 2), and one in men with advanced prostate cancer (HERO). We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, as a potential treatment for women undergoing assisted reproduction, such as in vitro fertilization (IVF).
Takeda Pharmaceuticals International AG has granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide. Over time, we intend to expand our development pipeline to include other potential treatments for women's health and prostate cancer.
Copyright West LLC. Share price minimum 15 minutes delayed. Market cap from previous market close.
Annual report which provides a comprehensive overview of the company for the past year
|10-K||EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA|
Quarterly report which provides a continuing view of a company's financial position
|10-Q||EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT|